Palifermin is efficacious in recipients of TBI-based but not chemotherapy-based allogeneic hematopoietic stem cell transplants Journal Article

   


Authors: Goldberg, J. D.; Zheng, J.; Castro-Malaspina, H.; Jakubowski, A. A.; Heller, G.; van den Brink, M. R. M.; Perales, M. A.
Article Title: Palifermin is efficacious in recipients of TBI-based but not chemotherapy-based allogeneic hematopoietic stem cell transplants
Abstract: Palifermin, a recombinant human keratinocyte growth factor, is commonly given to prevent mucositis following autologous transplantation. In the allogeneic hematopoietic stem cell transplant (allo-HSCT) setting, safety and efficacy data are limited. We conducted a retrospective study in 251 patients undergoing allo-HSCT, 154 of whom received peritransplant palifermin. In all patients, palifermin significantly decreased the mean number of days of total parenteral nutrition (TPN, 13 vs 16 days, P=0.006) and patient-controlled analgesia (PCA, 6 vs 10 days, P=0.023), as well as the length of initial hospital stay (LOS, 32 vs 37 days, P=0.014). However, the effect of palifermin was only significant in patients who received a TBI- but not BU-based chemotherapy conditioning regimen. In TBI recipients, palifermin decreased the mean number of days of TPN (13 vs 17 days, P<0.001) and PCA (7 vs 12 days, P=0.033), and the length of stay (32 vs 38 days, P=0.001). Palifermin did not affect GVHD, graft failure or relapse. Therefore, in the largest analysis with this patient population to date, we demonstrate that palifermin is safe in allo-HSCT patients, decreases TPN and PCA use and decreases LOS following TBI-based but not chemotherapy-based allo-HSCT. © 2013 Macmillan Publishers Limited.
Keywords: mucositis; allogeneic transplant; palifermin
Journal Title: Bone Marrow Transplantation
Volume: 48
Issue: 1
ISSN: 0268-3369
Publisher: Nature Publishing Group  
Date Published: 2013-01-01
Start Page: 99
End Page: 104
Language: English
DOI: 10.1038/bmt.2012.115
PROVIDER: scopus
PUBMED: 22750997
PMCID: PMC4054935
DOI/URL:

http://www.scopus.com/inward/record.url?eid=2-s2.0-84872123561&partnerID=40&md5=8dd45f7c7b02101ea0ad27a20d216f79
Notes: --- - "Export Date: 1 February 2013" - "CODEN: BMTRE" - "Source: Scopus"
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Junting Zheng
    200 Zheng
  2. Glenn Heller
    399 Heller
  3. Marcel R M Van Den Brink
    616 Van Den Brink
  4. Jenna Goldberg
    74 Goldberg
  5. Ann Jakubowski
    455 Jakubowski
  6. Miguel-Angel Perales
    913 Perales
  7. Hugo Castro-Malaspina
    333 Castro-Malaspina
Related MSK Work